BLI-1401 / ABVC BioPharma - LARVOL DELTA

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: BioLite, Inc. | Trial completion date: Feb 2023 ➔ Feb 2024 | Trial primary completion date: Oct 2022 ➔ Oct 2023

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - P2 | N=52 | Not yet recruiting | Sponsor: BioLite, Inc. | Trial completion date: Dec 2022 ➔ Jun 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation (GlobeNewswire) - "ABVC Biopharma, Inc...announced that it has expanded its co-development partnership with Rgene Corporation. BioKey...has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients...Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period....BLEX 404, the new drug under clinical development covered by the service agreement...with breast cancer and myelodysplastic syndromes (MDS) patients."

Licensing / partnership • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Rgene Corporation | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Oct 2022 ➔ Oct 2024

Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - P2; N=52; Not yet recruiting; Sponsor: BioLite, Inc.; Trial completion date: Mar 2022 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2; N=44; Not yet recruiting; Sponsor: BioLite, Inc.; Trial completion date: Feb 2022 ➔ Feb 2023; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • HER-2

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: Rgene Corporation; Trial completion date: Dec 2021 ➔ Dec 2022

Trial completion date

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - P2; N=52; Not yet recruiting; Sponsor: BioLite, Inc.; Trial primary completion date: Dec 2019 ➔ Dec 2021

Clinical • Trial primary completion date

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2; N=44; Not yet recruiting; Sponsor: BioLite, Inc.; Trial completion date: Sep 2018 ➔ Feb 2022; Trial primary completion date: Jun 2018 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date